 LOS GATOS, Calif., July 26, 2021 PRNewswire -- Aridis Pharmaceuticals, Inc. Nasdaq: ARDS, a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium CoVIC showed that the Companys COVID-19 monoclonal antibody mAb AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date. 